Cargando…
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
OBJECTIVES: Small-cell lung cancer (SCLC) is a lung malignancy with high relapse rates and poor survival outcomes. Treatment-resistant disease relapse occurs frequently and effective salvage therapies are urgently needed. MATERIALS AND METHODS: We aimed to define efficacy and safety of checkpoint in...
Autores principales: | Stratmann, Jan A., Timalsina, Radha, Atmaca, Akin, Rosery, Vivian, Frost, Nikolaj, Alt, Jürgen, Waller, Cornelius F., Reinmuth, Niels, Rohde, Gernot, Saalfeld, Felix C., von Rose, Aaron Becker, Acker, Fabian, Aspacher, Lukas, Möller, Miriam, Sebastian, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168937/ https://www.ncbi.nlm.nih.gov/pubmed/35677321 http://dx.doi.org/10.1177/17588359221097191 |
Ejemplares similares
-
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
por: Althoff, Friederike C., et al.
Publicado: (2023) -
KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021) -
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
por: Frost, Nikolaj, et al.
Publicado: (2021) -
German Cranial Reconstruction Registry (GCRR): protocol for a prospective, multicentre, open registry
por: Giese, Henrik, et al.
Publicado: (2015) -
Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor
por: Schröter, Nils, et al.
Publicado: (2020)